Comparison · NCT02857426-sae
PCNSL Cohort Nivolumab 240 mg (Q2W) vs PTL Cohort Nivolumab 240 mg (Q2W): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PCNSL Cohort Nivolumab 240 mg (Q2W) vs PTL Cohort Nivolumab 240 mg (Q2W): serious adverse events. Trial comparisons, record NCT02857426-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02857426-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.702 | 0.56 | 0.813 | wilson | |
| Risk in group 2 | 0.789 | 0.567 | 0.915 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0873 | -0.277 | 0.162 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.889 | 0.66 | 1.2 | log | |
| Odds ratio, group 1 over group 2 | 0.629 | 0.177 | 2.23 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on PCNSL Cohort Nivolumab 240 mg (Q2W) than on PTL Cohort Nivolumab 240 mg (Q2W) | 11.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PCNSL Cohort Nivolumab 240 mg (Q2W) | Nivolumab dosed to participants with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL).~Nivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion. | 33 | 47 | EG000 |
| Group 2 | PTL Cohort Nivolumab 240 mg (Q2W) | Nivolumab dosed to participants with relapsed/refractory Primary Testicular Lymphoma (PTL).~Nivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion. | 15 | 19 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From first dose to 100 days post last dose (up to approximately 48 months)
Source ClinicalTrials.gov
Trial
- Title
- A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
- NCT number
- NCT02857426
- Phases
- PHASE2
- Conditions
- Lymphoma
- Interventions
- Nivolumab
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2020-10-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02857426?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02857426-sae